Science Explorer Back to mapMap

Most cited papers from Cancer Research for the Ozarks

What are the most cited papers from Cancer Research for the Ozarks?

The most cited paper from Cancer Research for the Ozarks is "Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy" (Huib A.M. Kerstjens, Michael Engel, Ronald Dahl et al., 2012), with 668 citations. Next come "A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study" (179) and "A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer" (148).

Showing 50 of 71 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy Huib A.M. Kerstjens, Michael Engel, Ronald Dahl et al. · New England Journal of Medicine Open access 2 Sep 2012 668
2 A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study John Wendall Goodwin, John Crowley, Harmon J. Eyre et al. · Journal of Neuro-Oncology 1993 179
3 A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer Carol A Aghajanian, Virginia L. Filiaci, Don Steven Dizon et al. · Gynecologic Oncology Open access 24 May 2018 148
4 GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients Jay W. Carlson, James T. Kauderer, Alan David Hutson et al. · Gynecologic Oncology Open access 16 Dec 2019 128
5 A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study Bradley J. Monk, James T. Kauderer, Katherine Marie Moxley et al. · Gynecologic Oncology Open access 8 Oct 2018 125
6 A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study Agustin A. García, Michael W. Sill, Heather A. Lankes et al. · Gynecologic Oncology Open access 28 Oct 2011 122
7 A Prospective Analysis of the Influence of Older Age on Physician and Patient Decision-Making When Considering Enrollment in Breast Cancer Clinical Trials (SWOG S0316) Sara Hughes Javid, Joseph M. Unger, Julie R. Gralow et al. · The Oncologist Open access 20 Jun 2012 110
8 Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium Daniel Peter Petrylak, Catherine M. Tangen, Peter J. Van Veldhuizen et al. · British Journal of Urology 2 Nov 2009 106
9 Late Cardiac Effects of Adjuvant Chemotherapy in Breast Cancer Survivors Treated on Southwest Oncology Group Protocol S8897 Peter Ganz, Michael A. Hussey, Carol M. Moinpour et al. · Journal of Clinical Oncology Open access 29 Jan 2008 85
10 Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: A Gynecologic Oncology Group Study Allan L. Covens, Virginia L. Filiaci, Deborah J. Gersell et al. · Gynecologic Oncology 14 Nov 2010 77
11 A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes Sandhya Pruthi, Rui Qin, Shelby A. Terstreip et al. · Menopause The Journal of The North American Menopause Society Open access 4 Oct 2011 76
12 A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study Robert P. Whitehead, Sheryl McCoy, Saul E. Rivkin et al. · Investigational New Drugs 11 May 2006 71
13 Letting Go? Sharing Historical Authority in a User-Generated World Alex T. Primm · The Oral History Review 2012 70
14 Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study David Samuel Alberts, John A. Blessing, Lisa Michelle Landrum et al. · Gynecologic Oncology Open access 14 Sep 2012 70
15 GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function Jeanne Carter, Helen Q. Huang, Jane M. Armer et al. · Gynecologic Oncology Open access 24 Oct 2020 69
16 Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group David Scott Miller, John A. Blessing, Diane C. Bodurka et al. · Gynecologic Oncology 6 May 2008 66
17 Phase III Randomized Placebo-Controlled Trial of Two Doses of Megestrol Acetate as Treatment for Menopausal Symptoms in Women With Breast Cancer: Southwest Oncology Group Study 9626 John Wendall Goodwin, Stephanie Green, Carol M. Moinpour et al. · Journal of Clinical Oncology Open access 29 Mar 2008 65
18 GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE) Jeanne Carter, Helen Q. Huang, Jane M. Armer et al. · Gynecologic Oncology Open access Nov 2019 54
19 A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109 Peter J. Van Veldhuizen, James R. Faulkner, Primo N. Lara et al. · Cancer Chemotherapy and Pharmacology 24 Mar 2005 38
20 Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers Sandra A. Russo et al. · Gynecologic Oncology Open access 4 Nov 2020 34
21 Adjuvant continuous infusion 5-FU, whole-abdominal radiation, and tumor bed boost in high-risk stage III colon carcinoma: A southwest oncology group pilot study Carol J. Fabian, Shankar P. G. Giri, Norman C. Estes et al. · International Journal of Radiation Oncology*Biology*Physics May 1995 30
22 Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904 Robert Louis Coleman, James Moon, Anil K. Sood et al. · European Journal of Cancer Open access 4 Apr 2014 30
23 A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407) Kenneth J. Pienta, Emily I. Fisher, Mario A. Eisenberger et al. · The Prostate 2001 30
24 Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study William P. Tew, Michael W. Sill, Joan L. Walker et al. · Gynecologic Oncology Open access 31 Aug 2018 29
25 A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study Ursula A. Matulonis, Michael W. Sill, Vicky Makker et al. · Gynecologic Oncology Open access 23 Dec 2018 28
26 A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma: A Southwest Oncology Group study Laurence Elias, Brent A. Blumenstein, Julie Ann Kish et al. · Cancer Sep 1996 26
27 A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial John H. Farley, William E. Brady, David M. O’Malley et al. · Gynecologic Oncology Open access 14 Oct 2022 25
28 Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study Charles A. Kunos, Tomas Radivoyevitch, Fadi W. Abdul‐Karim et al. · Journal of Translational Medicine Open access 27 Apr 2012 25
29 Sequential Vinorelbine and Docetaxel in Advanced Non-small Cell Lung Cancer Patients Age 70 and Older and/or with a Performance Status of 2: A Phase II Trial of the Southwest Oncology Group (S0027) Paul Joseph Hesketh, Kari Chansky, Derick H. Lau et al. · Journal of Thoracic Oncology Open access Jul 2006 24
30 A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study Russell J. Schilder, Michael W. Sill, Heather A. Lankes et al. · Gynecologic Oncology Open access 13 Jan 2013 24
31 Second-line treatment of advanced measurable ovarian cancer with iproplatin: A Southwest oncology group study Geoffrey R. Weiss, Stephanie Green, David S. Alberts et al. · European Journal of Cancer and Clinical Oncology 1991 24
32 Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258 Aine Clements et al. · Gynecologic Oncology Open access 23 Jan 2025 23
33 Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study Amina Ismail Ahmed, Wei Deng, William P. Tew et al. · Gynecologic Oncology Open access 25 May 2018 21
34 A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study John K. Chan, Wei Deng, Robert V. Higgins et al. · Gynecologic Oncology Open access 18 Jul 2017 21
35 Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A southwest oncology group study Stephen K. Williamson, John J. Crowley, Robert B. Livingston et al. · Investigational New Drugs Mar 1995 20
36 Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study Arlene Odelia Siefker-Radtke, Matthew T. Campbell, Mark F. Munsell et al. · Urology Open access 23 Dec 2015 20
37 Cisplatin and novobiocin in the treatment of non-small cell lung cancer. A southwest oncology group study Georgiana Kehr Ellis, Robert B. Livingston, John Crowley et al. · Cancer 15 Jun 1991 19
38 Genome-wide host methylation profiling of anal and cervical carcinoma Erin M. Siegel, Abidemi O. Ajidahun, Anders Berglund et al. · PLoS ONE Open access 9 Dec 2021 18
39 Songbird nest success is positively related to restoration of pine–oak savanna and woodland in the Ozark Highlands, Missouri, USA Melissa C. Roach, Frank R. III Thompson, Todd Jones‐Farrand · Ornithological Applications Open access 6 Jun 2018 18
40 Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14 Jubilee Brown, Austin Miller, Laura L. Holman et al. · Gynecologic Oncology Open access 12 Sep 2024 17
41 Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group Bradley J. Monk, Michael W. Sill, Parviz Hanjani et al. · Gynecologic Oncology 8 Dec 2010 17
42 Effect of Transdermal Methylphenidate Wear Times on Sleep in Children With Attention Deficit Hyperactivity Disorder Arie Ashkenasi · Pediatric Neurology 22 Nov 2011 17
43 Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811 Corinne Doll, Jennifer Moughan, Alexander C. Klimowicz et al. · International Journal of Radiation Oncology*Biology*Physics Open access 23 Nov 2016 16
44 Phase II evaluation of echinomycin (NSC-526417) in patients with central nervous system malignancies Sarah A. Taylor, John Crowley, Jennette Townsend et al. · Journal of Neuro-Oncology Feb 1993 15
45 Dacarbazine and Outpatient Interleukin-2 in Treatment of Metastatic Malignant Melanoma: Phase II Southwest Oncology Group Trial Lawrence E. Flaherty, Pengfei Liu, William S. Fletcher et al. · JNCI Journal of the National Cancer Institute 3 Jun 1992 14
46 What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer Omali Pitiyarachchi, Michael Leonard Friedlander, James Java et al. · Gynecologic Oncology Open access 11 Jul 2022 12
47 Concurrent Cisplatin, Prolonged Oral Etoposide, and Vincristine plus Chest and Brain Irradiation for Limited Small Cell Lung Cancer: A Phase II Study of the Southwest Oncology Group (SWOG-9229) Charles R. Thomas, Dorothy J. Giroux, Keith J. Stelzer et al. · International Journal of Radiation Oncology*Biology*Physics 15 Mar 1998 11
48 Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial Maurie M. Markman, Tracy R. Glass, Harriet Olivia Smith et al. · Gynecologic Oncology Mar 2003 11
49 Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology) Charles E. Geyer, Hanna Bandos, Priya Rastogi et al. · Breast Cancer Research and Treatment Open access Mar 2022 10
50 Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas Mark M. Zalupski, Jacqueline Benedetti, Stanley P. Balcerzak et al. · Investigational New Drugs Dec 1993 10

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.